{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T01:53:12Z","timestamp":1777859592003,"version":"3.51.4"},"reference-count":22,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacy Practice"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>This study assessed the impact of an integrated health system specialty pharmacy (HSSP) on viral load (VL) suppression in HIV patients, compared to patients utilizing non-health system specialty pharmacies (non-HSSPs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a single-center, retrospective observational cohort study of patients \u226518 years with a HIV diagnosis and an encounter in the outpatient HIV clinic at an academic medical center associated with a HSSP, at least one order for an antiretroviral (ARV) medication, and at least one HIV-1 RNA VL result between January 2018 and May 2022. Outcomes included average rate of VL suppression and socio-demographic factors associated with VL suppression. Comparison of VL suppression between groups was tested using a generalized estimating equation logistic regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>From January 2018 to May 2022, 889 patients met the inclusion criteria; 326 provided VL results while filling at the HSSP and 681 had results while filling through a non-HSSP (118 patients provided results in both groups). Of the 5295 VL results, 90.6% reflected VL suppression, with the average rate of 91.0% in the HSSP group vs 86.0% in the non-HSSP group (adjusted OR = 1.89 95% CI: [1.40, 2.56]). Sex, ethnicity, and race were not associated with VL suppression. However, VL suppression decreased significantly with Charleson Comorbidity Index 1-3; increased with age; and increased over time from VL index date.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>HIV patients filling ARV therapy through a HSSP had a higher rate of VL suppression than those filling through non-HSSPs, highlighting the potential clinical benefit of this specialty pharmacy model.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/08971900251376796","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T17:20:03Z","timestamp":1757006403000},"page":"204-210","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Greater HIV Viral Load Suppression in Patients Using an Integrated Health System Specialty Pharmacy"],"prefix":"10.1177","volume":"39","author":[{"given":"Karen","family":"Salomon-Escoto","sequence":"first","affiliation":[{"name":"UMass Memorial Health and UMass Chan Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9021-9943","authenticated-orcid":false,"given":"Martha","family":"Stutsky","sequence":"additional","affiliation":[{"name":"Shields Health Solutions"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Reed","sequence":"additional","affiliation":[{"name":"UMass Chan Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica Y.","family":"Hinestroza Jordan","sequence":"additional","affiliation":[{"name":"University of Arizona, Banner Health"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Kay","sequence":"additional","affiliation":[{"name":"UMass Memorial Health and UMass Chan Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mireya","family":"Wessolossky","sequence":"additional","affiliation":[{"name":"UMass Memorial Health and UMass Chan Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,9,4]]},"reference":[{"key":"e_1_3_4_2_2","unstructured":"CDC. HIV treatment as prevention. HIV risk and prevention. https:\/\/www.cdc.gov\/hiv\/risk\/art\/. Accessed 27 March 2024."},{"key":"e_1_3_4_3_2","unstructured":"Primary care guidance for persons with human immunodeficiency virus: 2020 update by the HIV medicine association of the infectious diseases Society of America. Clinical Infectious Diseases. Oxford Academic. Accessed March 27 2024."},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-133-1-200007040-00004"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200003100-00008"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11904-007-0010-0"},{"key":"e_1_3_4_7_2","unstructured":"National Association of Specialty Pharmacy. What is specialty pharmacy? https:\/\/a8af0b.p3cdn2.secureserver.net\/wp-content\/uploads\/2024\/05\/What-is-Specialty-Pharmacy_Student_Aug23.pdf. Accessed 6 June 2024."},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxab277"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxac212"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp150701"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.18772"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2022.28.2.244"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1177\/10781552231190016"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2020.26.2.95"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"e_1_3_4_16_2","volume-title":"Statistical Software Components S456719","author":"Vicki Stagg","year":"2006","unstructured":"Vicki Stagg. CHARLSON: stata module to calculate Charlson index of comorbidity. In: Statistical Software Components S456719. Boston College Department of Economics; 2006. revised 13 Sep 2017."},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.mlr.0000182534.19832.83"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmacy7040163"},{"issue":"8","key":"e_1_3_4_19_2","first-page":"815","article-title":"Advancing patient care through specialty pharmacy services in an academic health system","volume":"23","author":"Bagwell A","year":"2017","unstructured":"Bagwell A, Kelley T, Carver A, Lee JB, Newman B. Advancing patient care through specialty pharmacy services in an academic health system. J Manag Care Spec Pharm. 2017;23(8):815-820.","journal-title":"J Manag Care Spec Pharm"},{"issue":"4","key":"e_1_3_4_20_2","first-page":"352","article-title":"Comparison of time to treatment initiation of specialty medications between an integrated health system specialty pharmacy and external specialty pharmacies","volume":"30","author":"Russell M","year":"2024","unstructured":"Russell M, McCoy H, Platt T, Zeltner M, Rhudy C. Comparison of time to treatment initiation of specialty medications between an integrated health system specialty pharmacy and external specialty pharmacies. J Manag Care Spec Pharm. 2024;30(4):352-362.","journal-title":"J Manag Care Spec Pharm"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25449"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cger.2012.01.008"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-013-0107-7"}],"container-title":["Journal of Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08971900251376796","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/08971900251376796","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08971900251376796","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:33:55Z","timestamp":1777509235000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/08971900251376796"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,4]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1177\/08971900251376796"],"URL":"https:\/\/doi.org\/10.1177\/08971900251376796","relation":{},"ISSN":["0897-1900","1531-1937"],"issn-type":[{"value":"0897-1900","type":"print"},{"value":"1531-1937","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,4]]}}}